Moderna shares tumble as FDA refuses to review flu vaccine application
Moderna shares dropped 14 percent today following the FDA refusal to review its flu vaccine application. The setback comes despite a strong start to 2026.
Insights:
The U.S. Food and Drug Administration in the United States 
US has refused to review the influenza vaccine approval application submitted by Moderna, Inc. , marking a significant regulatory setback for the company. Following the announcement on February 11, 2026, shares of the biotechnology firm opened 14% lower in Frankfurt, Germany 
DE. This sharp immediate share-price move represents a direct market reaction to the regulatory obstacle.
US has refused to review the influenza vaccine approval application submitted by Moderna, Inc. , marking a significant regulatory setback for the company. Following the announcement on February 11, 2026, shares of the biotechnology firm opened 14% lower in Frankfurt, Germany DE. This sharp immediate share-price move represents a direct market reaction to the regulatory obstacle.
